Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026)

Neumora Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 21.74% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 21.74% YoY), while the FY2025 annual figure was $11.5 million, up 15.23% from the prior year.
• Accumulated Expenses was $4.8 million for Q1 2026 at Neumora Therapeutics, down from $11.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $25.0 million in Q3 2025 to a low of $4.7 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $13.6 million across 5 years, with a median of $10.7 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 153.06% in 2023, then sank 63.69% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $8.4 million in 2022, then surged by 153.06% to $21.3 million in 2023, then slumped by 53.07% to $10.0 million in 2024, then rose by 15.23% to $11.5 million in 2025, then plunged by 58.07% to $4.8 million in 2026.
• The last three Accumulated Expenses figures came in at $4.8 million (Q1 2026), $11.5 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.